Natco Pharma begins sale of compulsorily licensed drug- Nexavar

09 Jul 2012 Evaluate

Pharmaceutical company, Natco Pharma, has begun the sale of its first compulsorily licensed drug, which is the generic version of Bayer's Nexavar. The drug, which is used for the treatment of advanced kidney cancer, is priced at Rs 8,880 for a pack of 120 tablets. The company is expecting to add about Rs 15 crore revenue from this drug initially.

In a major blow, Natco Pharma recently lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug - Copaxone.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.

Natco Pharma Share Price

897.05 1.15 (0.13%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×